Skip to main content

Table 2 Determinants of 25(OH)D (ng/ml) decrease on HAART

From: Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen

Variable

25(OH)D (CI) pre-HAART

25(OH)D (CI) post-HAART

Adj p

Population

24.6 (22.1;27.0)

22.0 (19.8;24.1)

0.001*

Sex

  

0.668

   M

25.6 (22.8;28.4)

22.8 (20.4;25.3)

 

   F

19.6 (14.8;24.4)

17.8 (14.0;21.6)

 

Skin color

  

0.195

   Light

26.7 (24.0;29.4)

23.6 (21.2;26.0)

 

   Dark

15.8 (11.9;19.7)

15.3 (11.6;19.0)

 

Pre-HAART sampling

  

0.127

   Winter

21.9 (18.1;25.6)

19.8 (16.2;23.5)

 

   Spring

22.1 (16.5;27.6)

22.4 (19.3;25.5)

 

   Summer

29.8 (24.2;35.4)

22.4 (19.7;29.0)

 

   Fall

24.8 (19.1;30.5)

22.5 (16.8;28.2)

 

Age

  

0.644

   <35 years

24.9 (21.0;28.7)

22.2 (18.6;25.8)

 

   35-50 years

24.2 (20.2;28.2)

21.2 (17.8;24.5)

 

   >50 years

24.8 (20.0;29.6)

24.2 (19.2;29.2)

 

Weight (Kg)

  

0.008

   ≤70

23.0 (19.4;26.6)

18.5 (16.2;20.9)

 

   >70

25.8 (22.4;29.2)

24.8 (21.4;28.1)

 

CD4 (CD4/mm3) nadir

  

0.160

   ≤200

25.4 (21.0;29.8)

21.3 (18.2;24.5)

 

   >200

24.1 (21.1;27.1)

22.3 (19.4;25.3)

 

CD4 (CD4/mm3) pre-HAART

  

0.174

   ≤200

25.9 (20.5;31.4)

21.5 (17.4;25.6)

 

   >200

24.1 (21.3;26.9)

22.1 (19.5;24.8)

 

Viral Load (log10)

  

0.666

   >5

25.7 (22.9;28.6)

22.9 (20.3;25.6)

 

   ≤5

21.7 (16.7;26.6)

19.6 (15.8;23.5)

 

HIV stage (CDC)

  

0.760

   A

25.4 (22.4;28.4)

22.7 (20.0;25.3)

 

   B

24.3 (18.0;30.5)

21.0 (15.7;26.4)

 

   C

19.8 (13.0;26.5)

18.7 (11.8;25.6)

 

Therapy

  

0.001

   NNRTI

26.6 (22.5;30.8)

21.6 (17.8;25.5)

 

   PI

22.6 (19.9;25.3)

22.3 (20.1;24.6)

 
  1. p: p-value for comparison between groups (linear regression); adj p: p-value from final multivariate model (after backwards elimination); CI: 95% confidence interval; * non adjusted p value